Cargando…
Drug Development in Tissue-Agnostic Indications
SIMPLE SUMMARY: The primary goal of any intervention in oncology is to improve overall survival and/or quality of life. The gold-standard approach to demonstrate that this goal has been achieved is a randomized controlled clinical trial. A better understanding of cancer biology has led to the molecu...
Autores principales: | du Rusquec, Pauline, Le Tourneau, Christophe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199632/ https://www.ncbi.nlm.nih.gov/pubmed/34199382 http://dx.doi.org/10.3390/cancers13112758 |
Ejemplares similares
-
Risks and benefits of anticancer drugs in advanced cancer patients: A systematic review and meta-analysis
por: Moreau Bachelard, Camille, et al.
Publicado: (2021) -
Developing Drugs for Tissue‐Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine
por: Seligson, Nathan D., et al.
Publicado: (2020) -
TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs
por: Han, Sun-Young
Publicado: (2021) -
Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications
por: Krebs, M.G., et al.
Publicado: (2021) -
Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?
por: Weis, Luiza N., et al.
Publicado: (2021)